Abstract
Antigenically different strains of mouse-adapted PR8 influenza A virus have been produced by 17 serial passages of the virus in the lungs of mice immunized with the homologous agent. Comparative serological tests show that the variant strains share antigenic components with the parent strain but the dominant antigen is different. By means of antibody absorption it was shown that the "new" antigenic component of the variant was already present in minor amounts up to the eighth passage and thereafter gained prominence with continued passage in vaccinated mice. Groups of mice vaccinated with either the PR8-S or T21 virus and having comparable antibody titers showed no growth of virus in the lungs following aid-borne challenge with homologous strains. On the other hand, following heterologous air-borne challenge no deaths occurred, but virus grew in the lungs of both groups of vaccinated mice. Almost unrestricted virus multiplication took place in the lungs of mice vaccinated with the parent strain and challenged with the PR8-T21 virus which resulted in extensive consolidation. Less virus grew in the lungs of the mice vaccinated with the variant strains and challenged with the PR8-S virus. In these animals only microscopic evidence of changes due to virus growth in the lungs was observed. The successful serial passage of PR8 influenza A virus in immunized animals was dependent on the initial selection of mice with uniformly low H.I. antibody titers as determined on tail blood, and the intranasal instillation of sufficient virus to favor the survival of those virus particles least related to the antibodies present. The epidemiological implications of these observations are discussed briefly.
Full Text
The Full Text of this article is available as a PDF (1.0 MB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ARCHETTI I., HORSFALL F. L., Jr Persistent antigenic variation of influenza A viruses after incomplete neutralization in ovo with heterologous immune serum. J Exp Med. 1950 Nov 1;92(5):441–462. doi: 10.1084/jem.92.5.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
- FRANCIS T., Jr Significance of antigenic variation of influenza viruses in relation to vaccination in man. Fed Proc. 1952 Sep;11(3):808–812. [PubMed] [Google Scholar]
- HILLEMAN M. R. System for measuring and designating antigenic components of influenza viruses with analyses of recently isolated strains. Proc Soc Exp Biol Med. 1951 Oct;78(1):208–215. doi: 10.3181/00379727-78-19023. [DOI] [PubMed] [Google Scholar]
- HORSFALL F. L., Jr Biological selection of antigenic variants. Fed Proc. 1952 Sep;11(3):804–807. [PubMed] [Google Scholar]
- JENSEN K. E., FRANCIS T., Jr The antigenic composition of influenza virus measured by antibody-absorption. J Exp Med. 1953 Dec;98(6):619–639. doi: 10.1084/jem.98.6.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
- LOOSLI C. G. The pathogenesis and pathology of experimental air-borne influenza virus A infections in mice. J Infect Dis. 1949 MarâApr;84(2):153–168. doi: 10.1093/infdis/84.2.153. [DOI] [PubMed] [Google Scholar]
- MAGILL T. P., JOTZ A. C. A pattern of influenza virus variation. J Bacteriol. 1952 Nov;64(5):619–628. doi: 10.1128/jb.64.5.619-628.1952. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Robertson O. H., Puck T. T., Lemon H. F., Loosli C. G. THE LETHAL EFFECT OF TRIETHYLENE GLYCOL VAPOR ON AIR-BORNE BACTERIA AND INFLUENZA VIRUS. Science. 1943 Feb 5;97(2510):142–144. doi: 10.1126/science.97.2510.142. [DOI] [PubMed] [Google Scholar]
- SALK J. E. An interpretation of the significance of influenza virus variation for the development of an effective vaccine. Bull N Y Acad Med. 1952 Nov;28(11):748–765. [PMC free article] [PubMed] [Google Scholar]
- TAYLOR R. M. Studies on survival of influenza virus between epidemics and antigenic variants of the virus. Am J Public Health Nations Health. 1949 Feb;39(2):171–178. doi: 10.2105/ajph.39.2.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- TYRRELL D. A. J., HORSFALL F. L., Jr A procedure which eliminates nonspecific inhibitor from human serum but does not affect specific antibodies against influenza viruses. J Immunol. 1952 Nov;69(5):563–574. [PubMed] [Google Scholar]